Valbenazine ($ Ingrezza)
VMAT2 inhibitor (reduces dopamine release)
- Tardive dyskinesia
Features
Dosing
40mg 1 qhs x7days, then 2 qhs #60
Management
Preferred version of the two as it is once a day and had a larger effect size in the trials.
If does not work or cannot afford, consider amantadine, levetiracetam, or ginkgo for TD.
RISK: QTC prolongation
EMR Text
Tardive dyskinesia
Valbenazine use based on FDA approval in tardive dyskinesia.
Valbenazine side effects, including cardiac (QTc), reviewed with patient.